Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | CEO & Executive Director | 7.07B | -- | 1959 |
| Dr. Aradhana Sarin M.D. | CFO & Executive Director | 3.43B | -- | 1974 |
| Ms. Pam P. Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | -- | -- | 1970 |
| Mr. Andrew P. Barnett | Head of Investor Relations | -- | -- | -- |
| Mr. Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | -- | -- | -- |
| Gonzalo Vina | Head of Global Media Relations | -- | -- | -- |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit | -- | -- | -- |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Haematology R&D | -- | -- | 1966 |
| Ms. Iskra Reic | Executive Vice President of International | -- | -- | -- |
| Mr. David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit | -- | -- | -- |
AstraZeneca PLC
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 94,300
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Corporate Governance
Upcoming Events
April 29, 2025 at 6:00 AM UTC
AstraZeneca PLC Earnings Date
Recent Events
February 21, 2025 at 12:00 AM UTC
Ex-Dividend Date